Question Bank › Strong facts, held-back story

Strong facts, held-back story

Strong facts, held-back story: management reports concrete strengthening but deliberately keeps expectations below it

Calls Tested
460
Answered YES
101
Hit Rate
22%
rare by design

Curis, Inc. (CRIS) — this company's answers

NO on the Q1 2016 call 2016-05-09 C
The model's full reasoning — Q1 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否同时(1)报告了已经发生的实际业务改善(如订单、销量、客户、活动、胜利、利用率或产出增加),并且(2)明显抑制了这种优势——故意将陈述的预期或框架保持在比报告事实所支持的更保守的水平。 首先,检查是否有实际改善的报告。在电话会议中,管理层提到了CUDC-907的临床进展:他们完成了第一阶段单药治疗组的入组,25名患者中有8名出现客观缓解(之前报告为7/16,现在为8/19可评估患者)。他们还提到,回顾性分析显示临床获益可能与MYC癌基因抑制相关,并据此设计了第二阶段试验。此外,CA170即将进入临床,预计成为首个口服检查点抑制剂。这些是正在发生的进展,但并非典型的商业指标(如订单、销量等),而是临床试验进展。然而,这些是实际发生的改善:缓解率提高,试验推进。 其次,检查管理层是否抑制了这种优势。在电话会议中,管理层对CUDC-907的回应率表示“非常健康”,但并未大幅提高预期。他们提到,与FDA讨论过阈值,但尚未给出具体数字。对于CA170,他们表示预期本季度进入临床,但未给出具体数据时间。他们强调需要更多数据。此外,对于Erivedge,他们提到合作伙伴启动了新研究,但未提及自身预期。 关键点:管理层是否在报告实际改善的同时,故意保持预期保守?在电话会议中,管理层没有明确说“我们看到了强劲增长,但我们保持保守”,而是描述了进展,但并未大幅上调预期。例如,对于CUDC-907,他们提到“我们期望这种患者富集能提高第二阶段试验成功的可能性”,但并未给出具体预期。对于CA170,他们只是说“预期进入临床”,没有给出时间表或预期数据。 然而,问题要求的是“报告已经发生的、实际的优势”,并且“明显抑制这种优势”。这里,优势是临床进展,但并非商业上的订单或销量。但问题说“whatever form fits the business”,所以临床试验进展可以视为业务优势。管理层确实报告了实际改善(缓解率提高,试验推进),但他们的陈述是否比事实更保守?他们提到“我们非常满意”但并未夸大。他们也没有明确说“我们保持保守”,但他们的语气是谨慎的,例如“我们预期患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体预期。 此外,他们提到“我们将在获得更多数据后与FDA讨论”,这表明他们不急于宣称成功。这可以视为一种抑制。 但问题要求“both halves come through in management's own words as one coherent posture”。管理层是否明确表示他们故意保持预期低于事实?在电话会议中,没有直接说“我们故意保守”,但他们的措辞可能暗示。例如,对于CUDC-907,他们提到“我们相信这个回应率是健康的”,但并未说“我们预期更高”。对于CA170,他们只是说“预期进入临床”,没有说“我们预期快速成功”。 然而,问题也指出,如果保守只是标准风险语言,则不算。这里,管理层的谨慎似乎与具体进展相关,例如他们强调需要更多数据,而不是仅仅说“有风险”。 但另一方面,管理层是否在报告实际改善的同时,明显抑制?他们报告了8/19的缓解率,但并未说“这比预期好”,而是说“我们相信这是健康的”。他们也没有提高全年指引(因为公司没有给出指引)。他们提到“我们期望患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体数字。 我认为,管理层确实报告了实际改善(缓解率提高,试验推进),并且他们的陈述相对保守,没有夸大。但这是否构成“明显抑制”?他们并没有说“我们看到了强劲势头,但我们保持保守”,而是以事实陈述方式描述进展。然而,他们的语气是谨慎的,例如“我们将在获得更多数据后与FDA讨论”,这暗示他们不急于宣称成功。 但问题要求“deliberately keeping stated expectations, forecasts, or framing more modest than the reported facts would support”。管理层没有给出明确的预期或预测,所以很难说他们是否保持更保守。他们只是描述进展,没有给出预期。因此,可能没有明显的差距。 此外,对于CA170,他们只是说“预期进入临床”,没有给出时间表或预期数据,这可能是正常的。 我认为,在这个电话会议中,管理层报告了实际进展,但并没有明显抑制优势。他们只是陈述事实,没有夸大,但也没有明确说“我们保持保守”。因此,可能不符合“明显抑制”的标准。 但让我们再仔细看:他们提到“我们期望这种患者富集能提高第二阶段试验成功的可能性”,这暗示他们相信数据,但并未给出具体预期。他们也没有说“我们预期高缓解率”。他们只是说“我们相信这是健康的”。 此外,对于CA170,他们提到“我们预期它成为世界首个口服检查点抑制剂”,这有点宣传性,但并非抑制。 总体而言,我认为管理层报告了实际改善,但他们的陈述并没有明显低于事实。他们只是谨慎地描述,没有夸大,但也没有故意压低预期。因此,可能不符合“明显抑制”的条件。 但问题要求“both halves come through”,所以如果只有一半,则回答NO。 我倾向于回答NO,因为虽然报告了实际改善,但抑制部分不明显。 然而,让我们再考虑:管理层提到“我们将在获得更多数据后与FDA讨论”,这可以视为一种抑制,因为他们没有立即宣称成功。但这是标准做法。 另外,他们提到“我们期望患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体预期。 我认为,没有明显的“抑制”行为。因此,答案应为NO。 但为了确认,检查是否有任何地方管理层明确说“我们保持保守”或类似。没有。 因此,回答NO。

← Back to the full CRIS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management BOTH (1) report concrete, already-occurring strength in the business — real improvement in the recent period such as rising orders, volumes, customers, activity, wins, utilization, or output, described as actually happening now rather than hoped for — AND (2) visibly HOLD THE STORY BACK from that strength — deliberately keeping stated expectations, forecasts, or framing more modest than the reported facts would support? Answer YES when both halves come through in management's own words as one coherent posture, in whatever form fits the business. The RESTRAINT half may show up in many ways, and any genuine expression of it counts — for example: management declining to raise, or raising only modestly, its outlook despite results plainly running ahead of it; management explicitly cautioning against extrapolating or annualizing the strong period even while confirming the strength is real; management choosing not to call the improvement a trend yet, saying it wants more quarters of evidence before it will; management emphasizing risks, execution work still ahead, or reasons for prudence at the very moment the underlying numbers are strengthening; management describing demand or momentum stronger than what it has built into its own plan or guidance; or management answering bullish analyst framings by talking the enthusiasm DOWN rather than up. What matters is the direction of the gap: the facts reported are running AHEAD of the story management is willing to tell, and the modesty is management's own deliberate choice — a stance of under-promising — rather than a response to genuine deterioration. Answer NO if the reported period is weak, mixed, or merely stabilizing, so there is no real strength for the story to lag. NO if management is promotional or freely extrapolates the strength — raising expectations in line with or beyond the results — however justified. NO if the caution reflects actual visible deterioration, softening demand, or specific problems management describes, rather than deliberate restraint amid strength. NO if the conservatism is only boilerplate risk language, standard safe-harbor phrasing, or routine 'prudent guidance' wording without a visible gap between reported facts and stated expectations. NO if the restraint is merely management declining to comment on distant years in the ordinary way. NO if the posture appears only in an analyst's characterization (such as calling guidance conservative) that management does not itself substantiate in how it talks about the business. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
PBR Petróleo Brasileiro S.A. - Petrobras Q4 2023 2024-03-08 D
NICE NICE Ltd. Q4 2023 2024-02-22 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
EGP EastGroup Properties, Inc. Q4 2023 2024-02-08 B
MET MetLife, Inc. Q4 2023 2024-02-01 B+
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
AEP American Electric Power Company, Inc. Q3 2023 2023-11-02 C+
PNNT PennantPark Investment Corporation Q3 2023 2023-08-10 B+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
DAL Delta Air Lines, Inc. Q2 2023 2023-07-13 A
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
THS TreeHouse Foods, Inc. Q1 2023 2023-05-08 B+
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
CALX Calix, Inc. Q1 2023 2023-04-20 C+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
UAL United Airlines Holdings, Inc. Q4 2022 2023-01-18 B
ICL ICL Group Ltd Q3 2022 2022-11-09 B+
MEC Mayville Engineering Company, Inc. Q3 2022 2022-11-05 B+
SYY Sysco Corporation Q1 2023 2022-11-01 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
CIVB Civista Bancshares, Inc. Q2 2022 2022-07-31 B
LIN Linde plc Q2 2022 2022-07-28 B+
PRGS Progress Software Corporation Q2 2022 2022-06-28 B+
SQM Sociedad Química y Minera de Chile S.A. Q1 2022 2022-05-19 C+
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
SOPH SOPHiA GENETICS SA Q4 2021 2022-03-15 C
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
VVV Valvoline Inc. Q1 2022 2022-02-09 C+
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
LC LendingClub Corporation Q4 2021 2022-01-26 A
ALHC Alignment Healthcare, Inc. Q3 2021 2021-11-06 B+
WMB The Williams Companies, Inc. Q3 2021 2021-11-02 B
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
MD Pediatrix Medical Group, Inc. Q3 2021 2021-10-28 B
CPRX Catalyst Pharmaceuticals, Inc. Q2 2021 2021-08-10 C+
AMC AMC Entertainment Holdings, Inc. Q2 2021 2021-08-09 D
UFI Unifi, Inc. Q4 2021 2021-08-07 B
CRS Carpenter Technology Corporation Q4 2021 2021-08-01 A
AX Axos Financial, Inc. Q4 2021 2021-07-29 C+
EHTH eHealth, Inc. Q2 2021 2021-07-29 F
JPM JPMorgan Chase & Co. Q2 2021 2021-07-13 A
T AT&T Inc. Q3 2018 2018-10-24 C+
CP Canadian Pacific Railway Limited Q2 2018 2018-07-19 B+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
HPE Hewlett Packard Enterprise Company Q2 2018 2018-05-22 B+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
HLX Helix Energy Solutions Group, Inc. Q1 2018 2018-04-24 B+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
TSLX Sixth Street Specialty Lending, Inc. Q4 2017 2018-02-22 C+
LII Lennox International Inc. Q4 2017 2018-02-06 B+
UNH UnitedHealth Group Incorporated Q4 2017 2018-01-16 A
RACE Ferrari N.V. Q3 2017 2017-11-02 C+
HTLF Heartland Financial USA, Inc. Q3 2017 2017-10-30 B+
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C
PII Polaris Inc. Q3 2017 2017-10-24 C+
BCE BCE Inc. Q2 2017 2017-08-05 B+
BIIB Biogen Inc. Q2 2017 2017-07-25 B
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
DAN Dana Incorporated Q1 2017 2017-05-02 B
SHOO Steven Madden, Ltd. Q1 2017 2017-04-21 C
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
AAT American Assets Trust, Inc. Q4 2016 2017-02-15 C+
BDC Belden Inc. Q4 2016 2017-02-02 B
BMO Bank of Montreal Q4 2016 2016-12-06 B
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
WAT Waters Corporation Q3 2016 2016-10-25 C
BOH Bank of Hawaii Corporation Q3 2016 2016-10-24 A
MAT Mattel, Inc. Q3 2016 2016-10-19 C
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+
CGNX Cognex Corporation Q2 2016 2016-08-01 A
TRV The Travelers Companies, Inc. Q2 2016 2016-07-21 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
INGR Ingredion Incorporated Q1 2016 2016-05-01 B+
SPR Spirit AeroSystems Holdings, Inc. Q1 2016 2016-04-29 D
ACCO ACCO Brands Corporation Q1 2016 2016-04-27 B+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
CAL Caleres, Inc. Q4 2015 2016-03-15 C+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C
HD The Home Depot, Inc. Q4 2015 2016-02-23 A
JHX James Hardie Industries plc Q3 2016 2016-02-19 B+

How the model reasoned

GTES · Q4 2021 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete, already-occurring strength in the business—rising orders, record backlog, book-to-build above 1, strong January order rates, specific design wins, and demand exceeding supply—while deliberately holding the story back by framing 2022 expectations as measured, pragmatic, and cautious, noting ongoing challenges through Q1 and not fully embedding the current momentum into the guidance range. This posture appears in their own words as they describe the facts running ahead of the outlook they are willing to share. The restraint is not mere boilerplate but a visible choice to under-promise relative to the reported strength.
BCOV · Q1 2018 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete strength in Q1 2018: revenue $41.2M exceeded high end of guidance, adjusted EBITDA positive $900k well above high end, recurring dollar retention 103% (multi-year high), strong bookings across businesses/geographies, notable wins including large auto company deal, Europe best 3+ years, completed commodity pricing reset, and digital marketing/enterprise activity showing productivity gains. They visibly hold the story back: full-year revenue guidance $165-168M (roughly flat vs. Q1 run-rate implying ~$164.8M), Q2 revenue guidance $41.
PII · Q3 2017 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND hold the story back from that strength? YES The transcript shows clear evidence of both elements in management's posture. They report concrete, already-occurring strength in the recent period—Q3 sales up 25% (adjusted), North American retail up 13% with RZR and NDN ahead, September as Polaris' highest retail month ever, August among top three 2017 months, off-road vehicles and Polaris retail up versus 2015 (not an easy comp), dealer inventory down 7%, and strong international/PG&A growth—while explicitly raising 2017 guidance (sales 18-19%, ORV/Snow mid-single digits, EPS $4.

More from the question bank

Ready-to-run scale already paid for and now Fresh change already executed, benefit mostlPersonal bests piling upOrder-of-magnitude gapQuietly replacing the old wayUpside surprise with durable, still-buildingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.